User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

The determinants of tumour immunogenicity.

Primary tabs

Blankenstein, Thomas Coulie, Pierre G. [UCL] Gilboa, Eli Jaffee, Elizabeth M

Many standard and targeted therapies, as well as radiotherapy, have been shown to induce an anti-tumour immune response, and immunotherapies rely on modulating the host immune system to induce an anti-tumour immune response. However, the immune response to such therapies is often reliant on the immunogenicity of a tumour. Tumour immunogenicity varies greatly between cancers of the same type in different individuals and between different types of cancer. So, what do we know about tumour immunogenicity and how might we therapeutically improve tumour immunogenicity? We asked four leading cancer immunologists around the world for their opinions on this important issue.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès restreint
Publication date 2012
Language Anglais
Journal information "Nature Reviews. Cancer" - Vol. 12, no.4, p. 307-13 (2012)
Peer reviewed yes
Publisher Nature Publishing Group ((United Kingdom) London)
issn 1474-175X
e-issn 1474-1768
Publication status Publié
Affiliation UCL - SSS/DDUV - Institut de Duve
MESH Subject Animals ; Tumor Escape ; Antigens, Neoplasm ; Cancer Vaccines ; Humans ; Immune System ; Immune System Processes ; Immunomodulation ; Mice ; Neoplasms
Links
  1. Willimsky Gerald, Czéh Melinda, Loddenkemper Christoph, Gellermann Johanna, Schmidt Karin, Wust Peter, Stein Harald, Blankenstein Thomas, Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness, 10.1084/jem.20072016
  2. Seung L. P., Cancer Res., 55, 5094 (1995)
  3. Preiss Susanne, Kammertoens Thomas, Lampert Christoph, Willimsky Gerald, Blankenstein Thomas, Tumor-induced antibodies resemble the response to tissue damage, 10.1002/ijc.20914
  4. Lennerz V., Fatho M., Gentilini C., Frye R. A., Lifke A., Ferel D., Wolfel C., Huber C., Wolfel T., The response of autologous T cells to a human melanoma is dominated by mutated neoantigens, 10.1073/pnas.0500090102
  5. Boon Thierry, Cerottini Jean-Charles, Van den Eynde Benoit, van der Bruggen Pierre, Van Pel Aline, Tumor Antigens Recognized by T Lymphocytes, 10.1146/annurev.iy.12.040194.002005
  6. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, 10.1126/science.1840703
  7. Gotter Jörn, Brors Benedikt, Hergenhahn Manfred, Kyewski Bruno, Medullary Epithelial Cells of the Human Thymus Express a Highly Diverse Selection of Tissue-specific Genes Colocalized in Chromosomal Clusters, 10.1084/jem.20031677
  8. Kloor Matthias, Michel Sara, von Knebel Doeberitz Magnus, Immune evasion of microsatellite unstable colorectal cancers, 10.1002/ijc.25283
  9. Casares Noelia, Pequignot Marie O., Tesniere Antoine, Ghiringhelli François, Roux Stéphan, Chaput Nathalie, Schmitt Elise, Hamai Ahmed, Hervas-Stubbs Sandra, Obeid Michel, Coutant Frédéric, Métivier Didier, Pichard Evelyne, Aucouturier Pierre, Pierron Gérard, Garrido Carmen, Zitvogel Laurence, Kroemer Guido, Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death, 10.1084/jem.20050915
  10. Fridman W. H., Galon J., Pages F., Tartour E., Sautes-Fridman C., Kroemer G., Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates, 10.1158/0008-5472.can-11-1316
  11. Hunder Naomi N., Wallen Herschel, Cao Jianhong, Hendricks Deborah W., Reilly John Z., Rodmyre Rebecca, Jungbluth Achim, Gnjatic Sacha, Thompson John A., Yee Cassian, Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1, 10.1056/nejmoa0800251
  12. Perez-Diez A., Joncker N. T., Choi K., Chan W. F. N., Anderson C. C., Lantz O., Matzinger P., CD4 cells can be more efficient at tumor rejection than CD8 cells, 10.1182/blood-2006-10-051318
  13. Zitvogel Laurence, Tesniere Antoine, Kroemer Guido, Cancer despite immunosurveillance: immunoselection and immunosubversion, 10.1038/nri1936
  14. Dunn Gavin P., Bruce Allen T., Ikeda Hiroaki, Old Lloyd J., Schreiber Robert D., Cancer immunoediting: from immunosurveillance to tumor escape, 10.1038/ni1102-991
  15. Klebanoff Christopher A., Gattinoni Luca, Restifo Nicholas P., CD8+ T-cell memory in tumor immunology and immunotherapy, 10.1111/j.0105-2896.2006.00391.x
  16. Tredan O., Galmarini C. M., Patel K., Tannock I. F., Drug Resistance and the Solid Tumor Microenvironment, 10.1093/jnci/djm135
  17. Hamzah Juliana, Jugold Manfred, Kiessling Fabian, Rigby Paul, Manzur Mitali, Marti Hugo H., Rabie Tamer, Kaden Sylvia, Gröne Hermann-Josef, Hämmerling Günter J., Arnold Bernd, Ganss Ruth, Vascular normalization in Rgs5-deficient tumours promotes immune destruction, 10.1038/nature06868
  18. Buckanovich Ronald J, Facciabene Andrea, Kim Sarah, Benencia Fabian, Sasaroli Dimitra, Balint Klara, Katsaros Dionysios, O'Brien-Jenkins Anne, Gimotty Phyllis A, Coukos George, Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy, 10.1038/nm1699
  19. BURNET MACFARLANE, IMMUNOLOGICAL FACTORS IN THE PROCESS OF CARCINOGENESIS, 10.1093/oxfordjournals.bmb.a070310
  20. Thomas L., Yale J. Biol. Med., 55, 329 (1982)
  21. Langman R.E., Cohn M., A minimal model for the self-nonself discrimination: a return to the basics, 10.1006/smim.2000.0231
  22. Dunn Gavin P., Old Lloyd J., Schreiber Robert D., The Immunobiology of Cancer Immunosurveillance and Immunoediting, 10.1016/j.immuni.2004.07.017
  23. Pradeu T., Carosella E. D., On the definition of a criterion of immunogenicity, 10.1073/pnas.0608683103
  24. Drake Charles G., Jaffee Elizabeth, Pardoll Drew M., Mechanisms of Immune Evasion by Tumors, Advances in Immunology (2006) ISBN:9780120224890 p.51-81, 10.1016/s0065-2776(06)90002-9
  25. Laheru Dan, Jaffee Elizabeth M., Immunotherapy for pancreatic cancer — science driving clinical progress, 10.1038/nrc1630
  26. Cohn Melvin, The immune system: a weapon of mass destruction invented by evolution to even the odds during the war of the DNAs, 10.1034/j.1600-065x.2002.18504.x
  27. Khong Hung T., Restifo Nicholas P., Natural selection of tumor variants in the generation of “tumor escape” phenotypes, 10.1038/ni1102-999
  28. Klein G., Klein E., Immune surveillance against virus-induced tumors and nonrejectability of spontaneous tumors: contrasting consequences of host versus tumor evolution., 10.1073/pnas.74.5.2121
  29. Shankaran Vijay, Ikeda Hiroaki, Bruce Allen T., White J. Michael, Swanson Paul E., Old Lloyd J., Schreiber Robert D., 10.1038/35074122
  30. Qin Zhihai, Blankenstein Thomas, A cancer immunosurveillance controversy, 10.1038/ni0104-3
  31. Uhr J. W., Pantel K., Controversies in clinical cancer dormancy, 10.1073/pnas.1106613108
  32. Garrido F., Int. J. Cancer, 127, 249 (2010)
  33. Gajewski Thomas F., Meng Yuru, Blank Christian, Brown Ian, Kacha Aalok, Kline Justin, Harlin Helena, Immune resistance orchestrated by the tumor microenvironment, 10.1111/j.1600-065x.2006.00442.x
  34. Uyttenhove Catherine, Pilotte Luc, Théate Ivan, Stroobant Vincent, Colau Didier, Parmentier Nicolas, Boon Thierry, Van den Eynde Benoît J, Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase, 10.1038/nm934
  35. Opitz Christiane A., Litzenburger Ulrike M., Sahm Felix, Ott Martina, Tritschler Isabel, Trump Saskia, Schumacher Theresa, Jestaedt Leonie, Schrenk Dieter, Weller Michael, Jugold Manfred, Guillemin Gilles J., Miller Christine L., Lutz Christian, Radlwimmer Bernhard, Lehmann Irina, von Deimling Andreas, Wick Wolfgang, Platten Michael, An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor, 10.1038/nature10491
  36. Pilotte L., Larrieu P., Stroobant V., Colau D., Dolusic E., Frederick R., De Plaen E., Uyttenhove C., Wouters J., Masereel B., Van den Eynde B. J., Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase, 10.1073/pnas.1113873109
  37. Demotte N., Wieers G., Van Der Smissen P., Moser M., Schmidt C., Thielemans K., Squifflet J.-L., Weynand B., Carrasco J., Lurquin C., Courtoy P. J., van der Bruggen P., A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice, 10.1158/0008-5472.can-10-0761
  38. Curiel Tyler J, Coukos George, Zou Linhua, Alvarez Xavier, Cheng Pui, Mottram Peter, Evdemon-Hogan Melina, Conejo-Garcia Jose R, Zhang Lin, Burow Matthew, Zhu Yun, Wei Shuang, Kryczek Ilona, Daniel Ben, Gordon Alan, Myers Leann, Lackner Andrew, Disis Mary L, Knutson Keith L, Chen Lieping, Zou Weiping, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival, 10.1038/nm1093
  39. Gobert M., Treilleux I., Bendriss-Vermare N., Bachelot T., Goddard-Leon S., Arfi V., Biota C., Doffin A. C., Durand I., Olive D., Perez S., Pasqual N., Faure C., Ray-Coquard I., Puisieux A., Caux C., Blay J.-Y., Menetrier-Caux C., Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome, 10.1158/0008-5472.can-08-2360
  40. Gabrilovich Dmitry I., Nagaraj Srinivas, Myeloid-derived suppressor cells as regulators of the immune system, 10.1038/nri2506
  41. Boon Thierry, Coulie Pierre G., Eynde Benoît J. Van den, Bruggen Pierre van der, HUMAN T CELL RESPONSES AGAINST MELANOMA, 10.1146/annurev.immunol.24.021605.090733
  42. Corbière Véronique, Chapiro Jacques, Stroobant Vincent, Ma Wenbin, Lurquin Christophe, Lethé Bernard, van Baren Nicolas, Van den Eynde Benoît J., Boon Thierry, Coulie Pierre G., Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases, 10.1158/0008-5472.can-10-2693
  43. Willimsky Gerald, Blankenstein Thomas, Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance, 10.1038/nature03954
  44. Neefjes J., Nature Rev. Immunol., 11, 823 (2011)
  45. Rezvani Katayoun, de Lavallade Hugues, Vaccination Strategies in Lymphomas and Leukaemias : Recent Progress, 10.2165/11593270-000000000-00000
  46. Scanlan. Matthew J., Gure. Ali O., Jungbluth. Achim A., Old. Lloyd J., Chen. Yao-Tseng, Cancer/testis antigens: an expanding family of targets for cancer immunotherapy, 10.1034/j.1600-065x.2002.18803.x
  47. Zheng Lei, Foley Kelly, Huang Lanqing, Leubner Ashley, Mo Guanglan, Olino Kelly, Edil Barish H., Mizuma Masamichi, Sharma Rajni, Le Dung T., Anders Robert A., Illei Peter B., Van Eyk Jennifer E., Maitra Anirban, Laheru Daniel, Jaffee Elizabeth M., Tyrosine 23 Phosphorylation-Dependent Cell-Surface Localization of Annexin A2 Is Required for Invasion and Metastases of Pancreatic Cancer, 10.1371/journal.pone.0019390
  48. Lampen Margit H, van Hall Thorbald, Strategies to counteract MHC-I defects in tumors, 10.1016/j.coi.2010.12.005
  49. Topalian Suzanne L., Weiner George J., Pardoll Drew M., Cancer Immunotherapy Comes of Age, 10.1200/jco.2011.38.0899
  50. Schietinger A., Delrow J. J., Basom R. S., Blattman J. N., Greenberg P. D., Rescued Tolerant CD8 T Cells Are Preprogrammed to Reestablish the Tolerant State, 10.1126/science.1214277
  51. Ganss R., Cancer Res., 58, 4673 (1998)
  52. IN THIS ISSUE, 10.1093/jnci/djs001
  53. Horowitz M. M., Blood, 75, 555 (1990)
  54. Wilde S., Sommermeyer D., Frankenberger B., Schiemann M., Milosevic S., Spranger S., Pohla H., Uckert W., Busch D. H., Schendel D. J., Dendritic cells pulsed with RNA encoding allogeneic MHC and antigen induce T cells with superior antitumor activity and higher TCR functional avidity, 10.1182/blood-2009-03-209387
  55. Li Liang-Ping, Lampert J Christoph, Chen Xiaojing, Leitao Catarina, Popović Jelena, Müller Werner, Blankenstein Thomas, Transgenic mice with a diverse human T cell antigen receptor repertoire, 10.1038/nm.2197
  56. Schumacher Ton N. M., T-cell-receptor gene therapy, 10.1038/nri841
  57. Offringa Rienk, Antigen choice in adoptive T-cell therapy of cancer, 10.1016/j.coi.2009.02.006
  58. Nair S., Synergy between tumor immunotherapy and antiangiogenic therapy, 10.1182/blood-2002-12-3738
  59. Niethammer Andreas G., Xiang Rong, Becker Jürgen C., Wodrich Harald, Pertl Ursula, Karsten Gabriele, Eliceiri Brian P., Reisfeld Ralph A., A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth, 10.1038/nm1202-794
  60. Pastor Fernando, Kolonias Despina, Giangrande Paloma H., Gilboa Eli, Induction of tumour immunity by targeted inhibition of nonsense-mediated mRNA decay, 10.1038/nature08999
  61. Pastor Fernando, Kolonias Despina, McNamara II James O, Gilboa Eli, Targeting 4-1BB Costimulation to Disseminated Tumor Lesions With Bi-specific Oligonucleotide Aptamers, 10.1038/mt.2011.145
  62. Gattinoni Luca, Zhong Xiao-Song, Palmer Douglas C, Ji Yun, Hinrichs Christian S, Yu Zhiya, Wrzesinski Claudia, Boni Andrea, Cassard Lydie, Garvin Lindsay M, Paulos Chrystal M, Muranski Pawel, Restifo Nicholas P, Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells, 10.1038/nm.1982
  63. Olive K. P., Jacobetz M. A., Davidson C. J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M. A., Caldwell M. E., Allard D., Frese K. K., DeNicola G., Feig C., Combs C., Winter S. P., Ireland-Zecchini H., Reichelt S., Howat W. J., Chang A., Dhara M., Wang L., Ruckert F., Grutzmann R., Pilarsky C., Izeradjene K., Hingorani S. R., Huang P., Davies S. E., Plunkett W., Egorin M., Hruban R. H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D. A., Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer, 10.1126/science.1171362
  64. Sugahara K. N., Teesalu T., Karmali P. P., Kotamraju V. R., Agemy L., Greenwald D. R., Ruoslahti E., Coadministration of a Tumor-Penetrating Peptide Enhances the Efficacy of Cancer Drugs, 10.1126/science.1183057
  65. Ma Yuting, Kepp Oliver, Ghiringhelli François, Apetoh Lionel, Aymeric Laetitia, Locher Clara, Tesniere Antoine, Martins Isabelle, Ly André, Haynes Nicole M., Smyth Mark J., Kroemer Guido, Zitvogel Laurence, Chemotherapy and radiotherapy: Cryptic anticancer vaccines, 10.1016/j.smim.2010.03.001
  66. Kantoff Philip W., Higano Celestia S., Shore Neal D., Berger E. Roy, Small Eric J., Penson David F., Redfern Charles H., Ferrari Anna C., Dreicer Robert, Sims Robert B., Xu Yi, Frohlich Mark W., Schellhammer Paul F., Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer, 10.1056/nejmoa1001294
  67. Hodi F. Stephen, O'Day Steven J., McDermott David F., Weber Robert W., Sosman Jeffrey A., Haanen John B., Gonzalez Rene, Robert Caroline, Schadendorf Dirk, Hassel Jessica C., Akerley Wallace, van den Eertwegh Alfons J.M., Lutzky Jose, Lorigan Paul, Vaubel Julia M., Linette Gerald P., Hogg David, Ottensmeier Christian H., Lebbé Celeste, Peschel Christian, Quirt Ian, Clark Joseph I., Wolchok Jedd D., Weber Jeffrey S., Tian Jason, Yellin Michael J., Nichol Geoffrey M., Hoos Axel, Urba Walter J., Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, 10.1056/nejmoa1003466
Bibliographic reference Blankenstein, Thomas ; Coulie, Pierre G. ; Gilboa, Eli ; Jaffee, Elizabeth M. The determinants of tumour immunogenicity.. In: Nature Reviews. Cancer, Vol. 12, no.4, p. 307-13 (2012)
Permanent URL http://hdl.handle.net/2078/121108